209 related articles for article (PubMed ID: 28400351)
41. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters.
Pirwany IR; Fleming R; Greer IA; Packard CJ; Sattar N
Clin Endocrinol (Oxf); 2001 Apr; 54(4):447-53. PubMed ID: 11318779
[TBL] [Abstract][Full Text] [Related]
42. A study of ghrelin and leptin levels and their relationship to metabolic profiles in obese and lean Saudi women with polycystic ovary syndrome (PCOS).
Daghestani MH; Daghestani M; Daghistani M; El-Mazny A; Bjørklund G; Chirumbolo S; Al Saggaf SH; Warsy A
Lipids Health Dis; 2018 Aug; 17(1):195. PubMed ID: 30131073
[TBL] [Abstract][Full Text] [Related]
43. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
44. Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS).
Barrea L; Arnone A; Annunziata G; Muscogiuri G; Laudisio D; Salzano C; Pugliese G; Colao A; Savastano S
Nutrients; 2019 Sep; 11(10):. PubMed ID: 31547562
[TBL] [Abstract][Full Text] [Related]
45. Low plasma atrial natriuretic peptide: a new piece in the puzzle of polycystic ovary syndrome.
Lauria PB; Del Puerto HL; Reis AM; Candido AL; Reis FM
J Clin Endocrinol Metab; 2013 Dec; 98(12):4882-9. PubMed ID: 24057296
[TBL] [Abstract][Full Text] [Related]
46. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Atiomo WU; Fox R; Condon JE; Shaw S; Friend J; Prentice AG; Wilkin TJ
Clin Endocrinol (Oxf); 2000 Apr; 52(4):487-92. PubMed ID: 10762292
[TBL] [Abstract][Full Text] [Related]
47. Obesity-related lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome.
Fulghesu A; Magnini R; Portoghese E; Angioni S; Minerba L; Melis GB
J Adolesc Health; 2010 May; 46(5):474-81. PubMed ID: 20413084
[TBL] [Abstract][Full Text] [Related]
48. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
49. Insulin resistance and β-cell dysfunction and the relationship with cardio-metabolic disorders among women with polycystic ovary syndrome.
Mu L; Zhao Y; Lai Y; Li R; Qiao J
Clin Endocrinol (Oxf); 2018 Dec; 89(6):779-788. PubMed ID: 30106166
[TBL] [Abstract][Full Text] [Related]
50. Association of Luteinizing hormone and LH receptor gene polymorphism with susceptibility of Polycystic ovary syndrome.
Deswal R; Nanda S; Dang AS
Syst Biol Reprod Med; 2019 Oct; 65(5):400-408. PubMed ID: 30958034
[TBL] [Abstract][Full Text] [Related]
51. Comparison of regional fat mass measurement by whole body DXA scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls.
Glintborg D; Petersen MH; Ravn P; Hermann AP; Andersen M
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1235-1243. PubMed ID: 27529295
[TBL] [Abstract][Full Text] [Related]
52. Polycystic ovary syndrome and abnormalities in glucose tolerance.
Bhattacharya SM
Int J Gynaecol Obstet; 2009 Apr; 105(1):29-31. PubMed ID: 19155002
[TBL] [Abstract][Full Text] [Related]
53. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199
[TBL] [Abstract][Full Text] [Related]
54. Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome.
Sam S; Scoccia B; Yalamanchi S; Mazzone T
Hum Reprod; 2015 Jun; 30(6):1358-64. PubMed ID: 25857311
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome.
Kachuei M; Jafari F; Kachuei A; Keshteli AH
Arch Gynecol Obstet; 2012 Mar; 285(3):853-6. PubMed ID: 21866332
[TBL] [Abstract][Full Text] [Related]
56. The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome.
Noyan V; Yucel A; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):200-5. PubMed ID: 15262356
[TBL] [Abstract][Full Text] [Related]
57. Assessment of oxytocin level, glucose metabolism components and cutoff values for oxytocin and anti-mullerian hormone in infertile PCOS women.
Jahromi BN; Dabbaghmanesh MH; Bakhshaie P; Parsanezhad ME; Anvar Z; Alborzi M; Zarei A; Bakhshaei M
Taiwan J Obstet Gynecol; 2018 Aug; 57(4):555-559. PubMed ID: 30122578
[TBL] [Abstract][Full Text] [Related]
58. Difference in dietary intake between women with polycystic ovary syndrome and healthy controls.
Douglas CC; Norris LE; Oster RA; Darnell BE; Azziz R; Gower BA
Fertil Steril; 2006 Aug; 86(2):411-7. PubMed ID: 16762348
[TBL] [Abstract][Full Text] [Related]
59. [A pilot study of serum anti-Mullerian hormone in diagnosis of polycystic ovary syndrome based on 2012 Chinese polycystic ovary syndrome diagnosis criteria].
Yang S; Ruan J; Huang W; Tan J; Zhang X; Feng X; Liu D; Fu J; Zhou L; Zhou M
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):819-24. PubMed ID: 26887768
[TBL] [Abstract][Full Text] [Related]
60. Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?
Meirow D; Raz I; Yossepowitch O; Brzezinski A; Rosler A; Schenker JG; Berry EM
Hum Reprod; 1996 Sep; 11(9):1848-53. PubMed ID: 8921052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
